ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Interactive Brokers

Interactive Brokers
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
S&P 500
5,048.42
-0.46%
US Tech 100
16,978.00
0.00%
Dow Jones
38,085.80
-0.98%
Brent Oil
88.355
0.23%
Bitcoin
64,325.73
-0.25%
Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ

  6. Inozyme Pharma Inc (INZY) Quote

Inozyme Pharma Inc

Inozyme Pharma Inc (INZY)

NASDAQ
4.33
0.00
(0.00%)
Closed April 26 4:00PM
Delayed by 15 minutes
0.00
0.00
(0.00%)
After Hours: -
Delayed by 15 minutes

Unlock more advanced trading tools

Join ADVFN today

Key stats and details

Current Price
4.33
Bid
4.01
Ask
4.33
Volume
-
0.00 Day's Range 0.00
2.689 52 Week Range 7.795
Market Cap
267.473M
Previous Close
4.33
Open
-
Last Trade
Last Trade Time
Financial Volume
-
VWAP
-
Average Volume (3m)
696,682
Shares Outstanding
61,771,977
Dividend Yield
-
PE Ratio
-3.76
Earnings Per Share (EPS)
-1.15
Revenue
-
Net Profit
-71.17M

About Inozyme Pharma Inc

Inozyme Pharma Inc is a rare disease biopharmaceutical company developing novel therapeutics for the treatment of diseases of abnormal mineralization impacting the vasculature, soft tissue and skeleton. The company is focused on developing a novel therapy to treat the rare genetic diseases of ENPP1 ... Inozyme Pharma Inc is a rare disease biopharmaceutical company developing novel therapeutics for the treatment of diseases of abnormal mineralization impacting the vasculature, soft tissue and skeleton. The company is focused on developing a novel therapy to treat the rare genetic diseases of ENPP1 and ABCC6 deficiencies. Its product candidate, INZ-701, is a soluble, recombinant, or genetically engineered, fusion protein that is designed to correct a defect in the mineralization pathway caused by ENPP1 and ABCC6 deficiencies. Show more

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Website
www.inozyme.com
Headquarters
Wilmington, Delaware, USA
Founded
1970
Inozyme Pharma Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker INZY. The last closing price for Inozyme Pharma was $4.33. Over the last year, Inozyme Pharma shares have traded in a share price range of $ 2.689 to $ 7.795.

Inozyme Pharma currently has 61,771,977 shares outstanding. The market capitalization of Inozyme Pharma is $267.47 million. Inozyme Pharma has a price to earnings ratio (PE ratio) of -3.76.

INZY Latest News

More News

Inozyme Pharma Announces Positive Topline Data from Ongoing Phase 1/2 Trials of INZ-701 in Adults with ABCC6 Deficiency (PXE) and ENPP1 Deficiency

- Favorable safety and immunogenicity profile in ABCC6 Deficiency, with clinical improvements in vascular pathology, visual function and patient reported outcomes (PROs) - - Natural history study...

April 08 2024
GlobeNewswire Inc.

Inozyme Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BOSTON, April 05, 2024 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY) (“Company” or “Inozyme”), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for...

April 05 2024
GlobeNewswire Inc.

Inozyme Pharma to Participate at the 23rd Annual Needham Virtual Healthcare Conference

BOSTON, April 02, 2024 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY) (“the Company” or “Inozyme”), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics...

April 02 2024
GlobeNewswire Inc.

Inozyme Pharma to Report Topline Data from Ongoing Phase 1/2 Trials of INZ-701 in Adults with ABCC6 Deficiency and ENPP1 Deficiency on April 8, 2024

- Company to host conference call and webcast featuring key opinion leaders on Monday, April 8, 2024 at 8:00 a.m. ET - BOSTON, March 26, 2024 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq:...

March 26 2024
GlobeNewswire Inc.

Inozyme Pharma Reports Full Year 2023 Financial Results and Provides Business Highlights

– Topline data from ongoing Phase 1/2 trials of INZ-701 in adults with ABCC6 Deficiency and ENPP1 Deficiency expected in early April – – Phase 1 trial of INZ-701 in end-stage kidney disease...

March 12 2024
GlobeNewswire Inc.

Inozyme Pharma to Participate in the TD Cowen 44th Annual Health Care Conference

BOSTON, Feb. 26, 2024 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY) (“Company” or “Inozyme”), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for...

February 26 2024
GlobeNewswire Inc.

Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]

February 14 2024
Edgar (US Regulatory)

Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]

February 12 2024
Edgar (US Regulatory)
PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-0.21-4.625550660794.544.634.186506414.40398443CS
4-3.33-43.47258485647.667.7954.188644805.51284156CS
12-1.23-22.12230215835.567.7954.186966825.89409488CS
261.4349.31034482762.97.7952.6895472985.12814965CS
52-1.35-23.76760563385.687.7952.6895740355.17123082CS
156-14.68-77.222514466119.0119.580.9914056564.63357019CS
260-13.6-75.850529838317.9331.64990.9913379765.37050542CS

Market Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
ISUNiSun Inc
$ 0.173
(84.04%)
19.93M
BRFHBarfresh Food Group Inc
$ 1.75
(69.90%)
44.33M
SGBXSafe and Green Holdings Corporation
$ 0.225
(56.14%)
136.91M
PCSAProcessa Pharmaceuticals Inc
$ 2.4137
(48.99%)
77.21M
BACKIMAC Holdings Inc
$ 5.065
(45.34%)
8.49M
EJHE Home Household Service Holdings Ltd
$ 0.767
(-73.64%)
12.36M
TVGNTevogen Bio Holdings Inc
$ 0.9057
(-39.62%)
328.69k
CSSEChicken Soup for the Soul Entertainment Inc
$ 0.265
(-37.69%)
16.75M
ATNIATN International Inc
$ 19.24
(-33.01%)
440.2k
BNAIBrand Engagement Network Inc
$ 2.59
(-30.56%)
234.29k
SQQQProShares UltraPro Short QQQ
$ 12.00
(1.61%)
167.48M
SGBXSafe and Green Holdings Corporation
$ 0.225
(56.14%)
136.91M
TSLATesla Inc
$ 170.18
(4.97%)
126.42M
ACONAclarion Inc
$ 0.383149
(33.04%)
115.53M
TQQQProShares UltraPro QQQ
$ 52.85
(-1.60%)
86.41M

INZY Discussion

View Posts
AJ Freely AJ Freely 9 months ago
$INZY - 👆Up 7% Pre-Market/ Current Price $5.12
Pivotal bioVenture Partners Fund I, L.P purchases
835k shares equal to $4m investment
👍️0
Monksdream Monksdream 9 months ago
INZY new 52 week high
👍️0
INFINITI INFINITI 1 year ago
Loading
👍️0
Jess070283 Jess070283 1 year ago
Have a feeling this about to squeeze into a halt soon…..
👍️0
tj9938 tj9938 1 year ago
Great week so far. Gotta keep it movin.
👍️0
tj9938 tj9938 1 year ago
Quietest board out there
👍️0
ErnieBilco ErnieBilco 2 years ago
Grabbed a starter here today
👍️0
crudeoil24 crudeoil24 2 years ago
INZ-701 is currently in a Phase 1/2 clinical trial for ENPP1 Deficiency. Inozyme Pharma was founded in 2017 by Joseph Schlessinger, Ph.D., Demetrios Braddock, M.D., Ph.D., and Axel Bolte, MSc, MBA, with technology developed by Dr. Braddock and licensed from Yale University. For more information, please visit www.inozyme.com
👍️0
crudeoil24 crudeoil24 2 years ago
Inozyme Pharma, Inc. is a clinical-stage rare disease biopharmaceutical company. The Company is focused on developing therapeutics for the treatment of diseases of abnormal mineralization impacting the vasculature, soft tissue and skeleton. It is also focused on developing a therapy to treat the rare genetic diseases of Ectonucleotide Pyrophosphatase/Phosphodiesterase 1 (ENPP1) and ATP-binding cassette sub-family C member 6 (ABCC6) deficiencies. The Company's lead product candidate, INZ-701, is a soluble, recombinant, or genetically engineered, fusion protein that is designed to correct a defect in the mineralization pathway caused by ENPP1 and ABCC6 deficiencies.
👍️0
crudeoil24 crudeoil24 2 years ago
Inozyme Pharma 13G Filing From Deep Track Capital Shows New 8.11% Stake

(i) Deep Track Capital, LP

(ii) Deep Track Biotechnology Master Fund, Ltd.

(iii) David Kroin

INZY
👍️0
tw0122 tw0122 2 years ago
I like the BioXc chart looks better. Thanks for all the good insight.
👍️0
crudeoil24 crudeoil24 2 years ago
The offering is expected to close on or about April 19, 2022
👍️0
tw0122 tw0122 2 years ago
This analyst know about the offering?
Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of abnormal mineralization, today announced the pricing of an underwritten offering of 16,276,987 shares of its common stock at a price of $3.69 per share and, to certain investors in lieu of common stock, pre-funded warrants to purchase 3,523,013 shares of common stock at a price of $3.6899 per pre-funded warrant, for aggregate gross proceeds of approximately $73 million, before deducting underwriting discounts and commissions and other offering expenses. The purchase price per share of each pre-funded warrant represents the per share public offering price for the common stock, minus the $0.0001 per share exercise price of such pre-funded warrant. All of the securities are being offered by Inozyme. The offering is expected to close on or about April 19, 2022, subject to customary closing conditions.
👍️0
crudeoil24 crudeoil24 2 years ago
PT > 33.00
👍️0
crudeoil24 crudeoil24 2 years ago
H.C. Wainwright analyst Edward White maintained a Buy rating on Inozyme Pharma (INZY – Research Report) yesterday and set a price target of $33.00. The company's shares closed last Tuesday at $3.89, close to its 52-week low of $3.54. According to TipRanks.com, White is ranked 0 out of 5 stars with an average return of -19.5% and a 25.5% success rate. White covers the Healthcare sector, focusing on stocks such as Spectrum Pharmaceuticals, Karyopharm Therapeutics, and Silverback Therapeutics. Inozyme Pharma has an analyst consensus of Strong Buy, with a price target consensus of $30.00, a 541.0% upside from current levels.
👍️0

Your Recent History

NASDAQ
INZY
Inozyme Pharma
Delayed Upgrade Clock
ADVFN Logo

United States
Company
Business
Popular
Get The App

Support: 1-888-992-3836 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved